Unveiling the Complete Biosynthetic Pathway of Azacitidine: A Rare 1,3,5-Triazine Nucleoside Derived From GTP.

Authors

Dan Wang, Qingxu Meng, Lingqi Hua, Mengjun Sun, Qianjin Kang, Min-Juan Xu, Linquan Bai

Published in

Angewandte Chemie (International ed. in English). Pages e1881662. Sep 29, 2026. Epub Sep 29, 2026.

Abstract

Azacitidine is a rare triazine-containing nucleoside and a clinically used DNA methyltransferase inhibitor for the treatment of myelodysplastic syndromes. Despite its medical importance, its biosynthetic pathway has remained elusive. Herein, we identified the azacitidine biosynthetic gene cluster (aza BGC) from Streptomyces mobaraensis IPIO2 using a resistance gene-guided comparative genomics strategy and elucidated its biosynthetic pathway via in vivo and in vitro studies. Unexpectedly, the bifunctional GTP cyclohydrolase I AzaE generates the triaminopyrimidine intermediate as the major product and H2NTP as a shunt product from GTP, diverging from canonical GCHI enzymes. The cofactor-independent cupin dioxygenase AzaA then assembles the 1,3,5-triazine scaffold using both O₂ and H₂O as oxygen donors, a mechanism unprecedented in nucleoside antibiotic biosynthesis. Subsequent decarboxylation by AzaB/AzaC, phosphoribosyl transfer by AzaD, and dephosphorylation by AzaG together with other endogenous hydrolases yield azacitidine. This work uncovers a distinct biosynthetic logic for triazine-containing nucleosides and provides a molecular basis for the synthetic biology-driven production of azacitidine.

PMID:
42806946
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.